Eupraxia Pharmaceuticals Raises $63.2M in Public Offering; Shares Tick Higher
Eupraxia Pharmaceuticals completed a public offering that generated approximately $63.2 million in gross proceeds, issuing 7,607,145 common shares and pre-funded warrants. The company said the funds will primarily support continued development of EP-104GI for eosinophilic esophagitis, including completion of preclinical work, Phase 2 trials and pre…